This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
May 19-22, 2025
Manchester Grand Hyatt San DiegoSan Diego, CA

David Butler, PhD
Chief Technology Officer at Hongene Biotech Corporation
Speaker

Profile

David Butler, PhD, is the Chief Technology Officer at Hongene Biotech Corporation, a fully integrated raw materials supplier and CDMO services provider that is focused on the RNA manufacturing space, the scope of which includes mRNA therapeutics, vaccines, siRNA, antisense oligonucleotides, diagnostics, and gene editing. Prior to Hongene, he led organizations driving drug discovery and development of oligonucleotide therapeutics as VP and Head of Medicinal Chemistry at Wave Life Sciences, VP and Head of Therapeutics Development at Alltrna, and VP and Head of Chemistry at Korro Bio. He also spent time as a Principal Scientist at Alnylam Pharmaceuticals developing early LNP technologies for siRNA delivery that were the progenitors of those used for mRNA related products today. He is passionate about team building, working with individuals and companies to help them succeed, and leveraging novel technologies to advance RNA medicines more efficiently and safely.

Agenda Sessions

  • Chemoenzymatic Ligation for siRNA and sgRNA Manufacturing: Recent Advances and Development Strategies

    12:20pm